Real-world outcomes of denosumab treatment in patients undergoing hemodialysis for osteoporosis: A 3-year observational study
Clinical Nephrology · 2026
DOI: 10.5414/cn111917 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Nephrology, 2026. Verfasst von Jung Soon Kim und 7 weiteren Autor:innen. Hauptthemen laut MEDLINE: Denosumab, Renal Dialysis, Osteoporosis, Kidney Failure, Chronic.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Kim, J. S., Kim, J. T., Lim, H. I., Kim, H. J., Jung, K. Y., Choi, H., Lim, J. A., & Lee, S. Y. (2026). Real-world outcomes of denosumab treatment in patients undergoing hemodialysis for osteoporosis: A 3-year observational study. Clinical Nephrology. https://doi.org/10.5414/cn111917
Vancouver
Kim JS, Kim JT, Lim HI, Kim HJ, Jung KY, Choi H, et al. Real-world outcomes of denosumab treatment in patients undergoing hemodialysis for osteoporosis: A 3-year observational study. Clinical Nephrology. 2026. doi:10.5414/cn111917
BibTeX
@article{Kim2026,
author = {Kim, Jung Soon and Kim, Jin Taek and Lim, Hong Il and Kim, Hyo-Jeong and Jung, Kyong Yeun and Choi, Hoonsung and Lim, Jung Ah and Lee, So Young},
title = {Real-world outcomes of denosumab treatment in patients undergoing hemodialysis for osteoporosis: A 3-year observational study},
journal = {Clinical Nephrology},
year = {2026},
doi = {10.5414/cn111917}
}
EUVIMED